Sofinnova Investments’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Sofinnova Investments’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-981,928	Closed	-$2.98M	–	74
2022 Q2	$2.98M	Sell	981,928 -499,291	-34%	-$2.43M	0.26%	48
2022 Q1	$10.1M	Sell	1,481,219 -101,558	-6%	-$724K	0.85%	31
2021 Q4	$13.2M	Buy	1,582,777 +945,430	+148%	+$7.79M	0.85%	36
2021 Q3	$4.74M	Buy	637,347 +12,591	+2%	+$78K	0.3%	57
2021 Q2	$4.25M	Buy	624,756 +112,934	+22%	+$938K	0.26%	54
2021 Q1	$5.26M	Sell	511,822 -413,458	-45%	-$4.53M	0.33%	48
2020 Q4	$6.48M	Buy	+925,280	New	+$7.2M	0.4%	44

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return

PFM Health Sciences San Francisco, California $950M AUM 57.92% 1-Year Est. Return

Cowen and Company New York $2.9B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return